Daewoong Pharmaceutical
Korean pharma maker of Nabota botulinum toxin, Fexuclue GERD drug, and Envlo diabetes pill.
On the record
Checkpoint: CGBio sale agreement with TA Associates expected to close
The call
Daewoong runs three separate, growing drug lines protected by regulatory approval and manufacturing know-how rather than by any AI-related edge.
Daewoong makes three prescription drugs: Nabota, a botox competitor; Fexuclue for acid reflux; and Envlo for diabetes. Each is regulated and licensed differently, which makes them genuinely hard for competitors like AbbVie, Sanofi, or Takeda to copy quickly, since they cannot just replicate the manufacturing secrets or steal the doctor relationships and pharmacy networks Daewoong has already built. The biggest unknown is whether a legal battle over Nabota's trade secrets in Korean courts gets resolved without damage, whether a planned sale of part of the company closes on schedule next year, and whether the company can keep its profits strong as cheaper copycat drugs flood the market from Samsung and other Korean rivals.
Why
01
AI pressure: None apparent. AI drug-discovery tools could speed rivals' pipelines someday, but no AI product is taking Daewoong's customers now. Could AI do the core job? Unlikely.
02
Bigger players: AbbVie (Allergan's Botox), Sanofi/Regeneron (Dupixent), Takeda (P-CAB GERD drugs). AbbVie's Botox still leads the global toxin market and Takeda's GERD drugs compete hard, but Nabota and Fexuclue keep growing revenue anyway. Could a giant copy it? No, they are blocked.
03
What protects it. Government drug approvals, its own toxin strain and manufacturing plant, and country-by-country distribution deals that rivals can't just copy overnight.
What would change this call
Outcome and timing of CGBio's sale to TA Associates (SPA targeted August 2026). Shows whether Daewoong Group cash is redirected toward or away from pharma pipeline investment.
Fexuclue gastric ulcer Phase 3 trial readout following its June 2026 IND approval. Indicates whether Fexuclue can expand indications and keep outpacing Takeda's P-CAB drugs in Korea.
Any Medytox botulinum trade-secret ruling or renewed litigation against Daewoong's Nabota strain. Would test whether Nabota's regulatory/IP moat holds against domestic rival Medytox.
Fexuclue gastric ulcer Phase 3 trial readout following its June 2026 IND approval. Indicates whether Fexuclue can expand indications and keep outpacing Takeda's P-CAB drugs in Korea.
Any Medytox botulinum trade-secret ruling or renewed litigation against Daewoong's Nabota strain. Would test whether Nabota's regulatory/IP moat holds against domestic rival Medytox.
Key numbers
- Nabota passed 1 trillion KRW in cumulative sales
- Envlo Middle East diabetes deal follows earlier $93m Acino licensing pact
- Fexuclue improved symptoms in 95.8% of patients in real-world study
Named risks
- CGBio sale to TA Associates may not close cleanly by targeted August 2026 SPA.
- Medytox litigation tail could reignite legal costs despite 2021 settlement.
- Biosimilar franchise faces crowding from Samsung Bioepis and Celltrion.
- Family/holding-company control concentration under Yoon Jae-seung raises governance concerns.
- Envlo and Fexuclue international growth depends on continued foreign regulatory approvals.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| AbbVie/Allergan (Botox) | gaining on | Nabota hit 1tn KRW cumulative sales with 57% CAGR 2019-2025, per 2026-07-13 |
| Medytox | contesting | Trade-secret litigation settled 2021 but Korean court friction lingers as of 2026-04-08 |
| Takeda | contesting | Fexuclue expanding indications, H. pylori approval May 2026, gastric ulcer IND June 2026 |
| Samsung Bioepis/Celltrion | contesting | Daewoong entering dupilumab biosimilar race via Chime Biologics deal, 2026-06-02 |
| Sanofi/Regeneron (Dupixent) | gaining on | New biosimilar partnership targets Dupixent market, announced 2026-06-02 |
Questions people ask
- Is Daewoong Pharmaceutical profitable in 2026?
- Yes. Daewoong Pharmaceutical (KRX:069620) reported FY2025 net income of about 195.86 billion KRW, up roughly 691.8% year over year, on revenue of about 1.57 trillion KRW, as of July 5, 2026, per stockanalysis.com.
- Who owns Daewoong Pharmaceutical?
- Daewoong Pharmaceutical is listed on the Korea Exchange (KRX:069620) and controlled by the Yoon family through holding company Daewoong Co., Ltd. Former chairman Yoon Jae-seung holds about 11.64% of the holding company, while National Pension Service of Korea holds roughly 5.5-5.7%, as of July 2026.
- What is Daewoong's biggest competitor in botulinum toxin?
- Daewoong's Nabota, sold as Jeuveau in the US and Nuceiva in Europe, competes mainly against AbbVie's Botox globally and domestic rival Medytox, with which it settled a trade-secret dispute in 2021 though residual Korean court proceedings lingered as of April 2026.
- Could AI replace Daewoong Pharmaceutical's drug pipeline?
- Unlikely soon. Daewoong licenses AI tools from partners like Innovo Therapeutics for IBD candidate INV-008 in May 2026 and Chime Biologics for a dupilumab biosimilar in June 2026, but its core moat, regulatory approvals, GMP manufacturing and clinical trial data, sits outside what AI models can directly replicate.
- Is Daewoong Pharmaceutical growing or shrinking?
- Growing. FY2025 revenue rose 10.42% YoY to about 1.57 trillion KRW, Nabota crossed 1 trillion KRW in cumulative sales by June 30, 2026 after averaging 57% annual growth from 2019-2025, and headcount grew 24.2% YoY to about 2,761 employees as of December 2025.
- What happened with Daewoong's CGBio sale?
- After talks with IMM Private Equity collapsed over a non-compete clause, Daewoong named TA Associates as preferred bidder for group affiliate CGBio, valued at roughly 700 billion KRW, in July 2026, with a share purchase agreement targeted for August 2026.
Timeline
- 2026-07-23Envlo Middle East launch partnership via Daewoong Arcera Life Sciences announced
- 2026-07-13Nabota surpasses 1 trillion KRW cumulative sales, 12 years after Korean launch
- 2026-07-10TA Associates named preferred bidder for CGBio after IMM talks collapse
- 2026-07-09Envlo fatty-liver benefit study published
- 2026-07-03Fexuclue real-world data shows 95.8% symptom improvement in interim PMS analysis
- 2026-06-24Fexuclue gastric ulcer Phase 3 IND approved
- 2026-06-02Chime Biologics and Daewoong announce dupilumab biosimilar partnership
- 2026-05-12Daewoong in-licenses AI-discovered IBD candidate INV-008 from Innovo Therapeutics
- 2026-05-01Fexuclue approved for H. pylori eradication
Head to head
Revision history
25 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Daewoong Pharmaceutical (KRX) Revenue (2026-07-05)
- 069620) Stock Price & Overview
- Daewoong's Nabota tops W1tr in cumulative sales (2026-07-13)
- Daewoong's Fexuclue wins phase 3 IND approval for gastric ulcer indication (2026-06-24)
- Daewoong's GERD drug improves symptoms in 95.8% of patients in real-world study (2026-07-03)
- Korea's Daewoong Pharma inks agreement to launch Enavogliflozin in Middle East (2026-07-23)
- Daewoong's Envlo improves fatty liver markers (2026-07-09)
- Daewoong Pharmaceutical Number of Employees 2026 (2026-06-29)
- Daewoong Pharmaceutical Co. Ltd. Profile (2025-08-25)
- Who Owns Daewoong? 003090 Ownership Shareholders (2026-07-02)
- CGBio restructures before sale as Yoon Jae-seung moves to tighten control in Korea (2026-02-04)
- Daewoong picks TA Associates as preferred bidder for CGBio after IMM talks collapse (2026-07-10)